Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 8:24 PM ET

Biotechnology

Company Overview of Cubist Pharmaceuticals Inc.

Company Overview

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. The company offers CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD); and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. It also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatm...

65 Hayden Avenue

Lexington, MA 02421

United States

Founded in 1992

873 Employees

Phone:

781-860-8660

Key Executives for Cubist Pharmaceuticals Inc.

Chief Financial Officer and Senior Vice President
Age: 49
Chief Operating Officer and Executive Vice President
Age: 52
Chief Compliance Officer and Senior Vice President of Global Compliance & Risk
Senior Vice President of Scientific Affairs
Age: 67
Senior Vice President of Commercial Operations
Age: 57
Compensation as of Fiscal Year 2015.

Cubist Pharmaceuticals Inc. Key Developments

Cubist Pharmaceuticals Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015

Cubist Pharmaceuticals Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Presentation Date & Speakers: May-26-2015, Rob Perez. May-27-2015, Rob Perez.

Cubist Pharmaceuticals Files Form 15

Cubist Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, $0.001 par value under the Securities Exchange Act of 1934, as amended.

Cubist Pharmaceuticals Inc.(NasdaqGM:CBST) dropped from S&P 1000 Index

Cubist Pharmaceuticals Inc.(NasdaqGM:CBST) dropped from S&P 1000 Index

Similar Private Companies By Industry

Company Name Region
Nebraska Cultures, Inc. United States
APSE, LLC United States
Aura Biosciences, Inc. United States
AGY Therapeutics Inc. United States
Arrogene, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 8, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cubist Pharmaceuticals Inc., please visit www.cubist.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.